An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia

Previous studies have demonstrated that vascular endothelial growth factor (VEGF) is upregulated in patients with hereditary hemorrhagic telangiectasia (HHT). The use of Bevacizumab as an anti-angiogenic treatment agent seems promising. The purpose of the present in vitro study was to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadick, Haneen, Schäfer, Elena, Weiss, Christel, Rotter, Nicole, Müller, Cornelia Emika, Birk, Richard, Sadick, Maliha, Häussler, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366282/
https://www.ncbi.nlm.nih.gov/pubmed/35978926
http://dx.doi.org/10.3892/etm.2022.11493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366282/
https://www.ncbi.nlm.nih.gov/pubmed/35978926
http://dx.doi.org/10.3892/etm.2022.11493

Ejemplares similares